263 related articles for article (PubMed ID: 33242557)
1. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
[TBL] [Abstract][Full Text] [Related]
2. The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients.
Stoehr CG; Walter B; Denzinger S; Ghiorzo P; Sturm RA; Hinze R; Moch H; Junker K; Hartmann A; Stoehr R
Pathobiology; 2016; 83(4):165-9. PubMed ID: 26999813
[TBL] [Abstract][Full Text] [Related]
3. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
4. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
5. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.
Gupta S; Erickson LA; Lohse CM; Shen W; Pitel BA; Knight SM; Halling KC; Herrera-Hernandez L; Boorjian SA; Thompson RH; Leibovich BC; Jimenez RE; Cheville JC
JAMA Netw Open; 2021 Nov; 4(11):e2132615. PubMed ID: 34767027
[TBL] [Abstract][Full Text] [Related]
7. Exploring the hereditary background of renal cancer in Denmark.
Christensen MB; Wadt K; Jensen UB; Lautrup CK; Bojesen A; Krogh LN; Overeem Hansen TV; Gerdes AM
PLoS One; 2019; 14(4):e0215725. PubMed ID: 31034483
[TBL] [Abstract][Full Text] [Related]
8. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
[TBL] [Abstract][Full Text] [Related]
9. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
[TBL] [Abstract][Full Text] [Related]
10. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
Bertolotto C; Lesueur F; Giuliano S; Strub T; de Lichy M; Bille K; Dessen P; d'Hayer B; Mohamdi H; Remenieras A; Maubec E; de la Fouchardière A; Molinié V; Vabres P; Dalle S; Poulalhon N; Martin-Denavit T; Thomas L; Andry-Benzaquen P; Dupin N; Boitier F; Rossi A; Perrot JL; Labeille B; Robert C; Escudier B; Caron O; Brugières L; Saule S; Gardie B; Gad S; Richard S; Couturier J; Teh BT; Ghiorzo P; Pastorino L; Puig S; Badenas C; Olsson H; Ingvar C; Rouleau E; Lidereau R; Bahadoran P; Vielh P; Corda E; Blanché H; Zelenika D; Galan P; ; Aubin F; Bachollet B; Becuwe C; Berthet P; Bignon YJ; Bonadona V; Bonafe JL; Bonnet-Dupeyron MN; Cambazard F; Chevrant-Breton J; Coupier I; Dalac S; Demange L; d'Incan M; Dugast C; Faivre L; Vincent-Fétita L; Gauthier-Villars M; Gilbert B; Grange F; Grob JJ; Humbert P; Janin N; Joly P; Kerob D; Lasset C; Leroux D; Levang J; Limacher JM; Livideanu C; Longy M; Lortholary A; Stoppa-Lyonnet D; Mansard S; Mansuy L; Marrou K; Matéus C; Maugard C; Meyer N; Nogues C; Souteyrand P; Venat-Bouvet L; Zattara H; Chaudru V; Lenoir GM; Lathrop M; Davidson I; Avril MF; Demenais F; Ballotti R; Bressac-de Paillerets B
Nature; 2011 Oct; 480(7375):94-8. PubMed ID: 22012259
[TBL] [Abstract][Full Text] [Related]
11. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract][Full Text] [Related]
12. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation.
Filler T; Verkarre V; Peyrottes A; Poinard F; Lupo A; Dariane C; Hurel S; Timsit MO; Mejean A; Audenet F
Fr J Urol; 2024 Mar; 34(2):102569. PubMed ID: 38717457
[TBL] [Abstract][Full Text] [Related]
14. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
15. A Tale of 2 Morphologies: Diagnostic Pitfalls in
Sharma AE; Parilla M; Wanjari P; Segal JP; Antic T
Int J Surg Pathol; 2021 Feb; 29(1):21-29. PubMed ID: 32886007
[TBL] [Abstract][Full Text] [Related]
16. PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma.
Schmidt LS; Vocke CD; Ricketts CJ; Blake Z; Choo KK; Nielsen D; Gautam R; Crooks DR; Reynolds KL; Krolus JL; Bashyal M; Karim B; Cowen EW; Malayeri AA; Merino MJ; Srinivasan R; Ball MW; Zbar B; Marston Linehan W
Urology; 2023 Sep; 179():58-70. PubMed ID: 37331486
[TBL] [Abstract][Full Text] [Related]
17. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
19. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
20. MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics.
Magers MJ; Udager AM; Mehra R
Arch Pathol Lab Med; 2015 Oct; 139(10):1224-33. PubMed ID: 26414466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
